Publication Date
| In 2026 | 0 |
| Since 2025 | 0 |
| Since 2022 (last 5 years) | 0 |
| Since 2017 (last 10 years) | 0 |
| Since 2007 (last 20 years) | 1 |
Descriptor
| Adolescents | 1 |
| Autism | 1 |
| Behavior Change | 1 |
| Check Lists | 1 |
| Children | 1 |
| Control Groups | 1 |
| Drug Therapy | 1 |
| Experimental Groups | 1 |
| Outcomes of Treatment | 1 |
| Severity (of Disability) | 1 |
| Symptoms (Individual… | 1 |
| More ▼ | |
Source
| Journal of Autism and… | 1 |
Author
| Aman, Michael | 1 |
| Hough, David | 1 |
| Karcher, Keith | 1 |
| Kent, Justine M. | 1 |
| Kushner, Stuart | 1 |
| Ness, Seth | 1 |
| Ning, Xiaoping | 1 |
| Singh, Jaskaran | 1 |
Publication Type
| Journal Articles | 1 |
| Reports - Research | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
| Aberrant Behavior Checklist | 1 |
| Obsessive Compulsive Scale | 1 |
What Works Clearinghouse Rating
Peer reviewed
Direct linkKent, Justine M.; Kushner, Stuart; Ning, Xiaoping; Karcher, Keith; Ness, Seth; Aman, Michael; Singh, Jaskaran; Hough, David – Journal of Autism and Developmental Disorders, 2013
Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5-17 years), received risperidone (low-dose: 0.125 mg/day [20 to <45 kg], 0.175 mg/day [>45 kg] or high-dose: 1.25 mg/day [20 to <45 kg], 1.75 mg/day [>45 kg]) or placebo. Mean baseline (range 27-29) to endpoint change…
Descriptors: Drug Therapy, Children, Adolescents, Autism
